Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Vertex receives approval from European Commission for cystic fibrosis drug

Vertex Pharmaceuticals Incorporated, a biotechnology company, has received approval from the European Commission, or EC, for KALYDECO for people with cystic fibrosis, or CF, ages six and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

Ono Pharmaceutical reports lower Q1 profit, provides annual outlook

Ono Pharmaceutical Co., Ltd. has reported a profit attributable to owners of the parent company of JPY2.91 billion, or JPY27.43 per basic share, for the first quarter ended June 30, 2014, compared to JPY7.99 billion, or JPY75.38 per basic share, for the same quarter ended June 30, 2013. For the year ending March 31, 2015, the company expects revenue to be JPY139 billion, profit to be JPY16 billion and basic earnings per share to be JPY150.93.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

QLT Q2 net loss up

QLT Inc. has reported a net loss and comprehensive loss of $8.64 million, or $0.17 loss per share, for the second quarter ended June 30, 2014, compared to a net loss and comprehensive loss of $6.2 million, or $0.12 loss per share, for the same quarter ended June 30, 2013.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

Baxano Surgical receives two patents for surgical technologies from USPTO

Baxano Surgical, Inc., a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, has received two patents from US Patent and Trademark Office, or USPTO, on key Baxano Surgical technologies, bringing the company's patent portfolio to 92 patents in the US.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

Bruker launches new software package for EBSD pattern simulation

Bruker Corporation, a provider of scientific instruments and solutions, has introduced ESPRIT DynamicS, a software tool for high resolution simulation of electron backscatter diffraction, or EBSD, patterns.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

Catamaran reports higher Q2 net income, provides outlook for 2014

Catamaran Corporation has reported a net income attributable to the company of $71.43 million, or $0.34 per diluted share, for the second quarter ended June 30, 2014, compared to $63.42 million, or $0.31 per diluted share, for the same quarter ended June 30, 2013. For 2014, the company expects fully diluted GAAP earnings per share to be in the range of $1.4 to $1.5.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

Quintiles reports higher net income for Q2, updates guidance for 2014

Quintiles Transnational Holdings Inc. has reported that net income attributable to the company for the second quarter ended June 30, 2014 was $85.12 million, or $0.64 per diluted share, compared to $38.52 million, or $0.30 per diluted share, for the same quarter ended June 30, 2013. The company has updated its 2014 guidance, which includes service revenues estimated to be between $4.20 billion and $4.24 billion.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

BioTelemetry Q2 net loss up

BioTelemetry, Inc., a wireless medical technology company, has reported that net loss for the second quarter ended June 30, 2014 was $3.99 million, or $0.15 loss per share, compared to a net loss of $2.3 million, or $0.09 loss per share, for the same quarter ended June 30, 2013.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

NPS Pharmaceuticals initiates Phase IIa autosomal dominant hypocalcemia study

NPS Pharmaceuticals, Inc., a biopharmaceutical company, has initiated a Phase IIa study to evaluate the safety and tolerability of NPSP795 in adult patients with autosomal dominant hypocalcemia, or ADH.

Published By MarketLine
20 Aug 2014
NewsWire
NewsWire

Onxeo H1 net loss up

Onxeo SA has reported a net loss attributable to the equity holders of the parent company of E12.95 million, or E0.41 loss per share, for the first six months ended June 30, 2014, compared to a net loss attributable to the equity holders of the parent company of E7.49 million, or E0.41 loss per share, for the same period ended June 30, 2013.

Published By MarketLine
20 Aug 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.